Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3600-0.0400 (-1.67%)
At close: 04:00PM EDT
2.7500 +0.39 (+16.53%)
After hours: 06:23PM EDT
Advertisement
Sign in to post a message.
  • C
    Cured
    I expect a significant Upfront Money with the New $BMY partnerhsip: Gps Opdivo just more than doubled survival for mesothelioma patients. "results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
    Bullish
  • D
    Dude
    Downside risk Nil Upside Potential 2 to 3,000% market cap of 50 when comps get bought for billions.
  • J
    Joe
    2 year cash runway, a FDA Green light to generate $800M annually 5+ months - Market Cap 48.669M???
    If anyone likes money. Now is A great time. Best Short term investment any of us will see for a Long time.
  • k
    kC
    I love buying short sold shares the best
  • C
    Cured
    Half the patients remain - Gps + Opdivo + Yervoy will become the SOC. $1B $BMY License for these rights
    "results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
    Bullish
  • C
    Cured
    The Chair of MD Andersons Leukemia dept running the GPS Phase 3, sees the trial Data, and requested Expanded Access beyond the Cr2 treated patients, to include Cr 1 and ASCT patients.
    Essentially, Confirms Gps is doing what it should and the ultimate overall AML market is 5x CR 2 appx $800M.
    Bullish
  • g
    greg
    $193 M in milestone money remaining, eliminates future dilution. $25M payment when the P3 hits followed by another $50 shortly thereafter.
  • C
    Cured
    At some point the Market will begin to Appreciate all the. Facts the SLS CEO has stacked up. - 2 year cash runway - a FDA Green light to $800M in annual revenue in a matter of months
    - $200M 3D license deal, and as mentioned, the P3 triggers the big money - a $25M milestone payment + another $25M in short order.
    - There will be no offerings to save all the shorts outstanding
    Bullish
  • M
    MauiRunner
    A glimpse of SLS's not too distant Future: Direct AML Gps Comp: Hardly anyone thought much of Celator Pharma. The cancer drug developer’s stock was trading for less than $2 a share on thin volumes.

    Today, the Ewing, N.J.-based maker of a drug for acute myeloid leukemia said it’s getting acquired by Dublin, Ireland-based Jazz Pharmaceuticals for $30.25 a share—a total value of $1.5 billion. The price represents a 72% premium over Celator’s previous market close on Friday. Some positive clinical trial results from a cancer trial drove its value all the way from $1.68 a share in March 14 to $30.25 on May 31.
    Bullish
  • L
    Lutz
    3.0000 +0.60 (+25.00%)
    Pre-Market: 06:42AM EDT
  • J
    Joe
    2 year cash runway, a FDA Green light to $800M in annual revenue in just 5+ months
    3D licensing deal is for $193 M - the big money starts with the P3 triggers a $25M milestone payment + another 25M in short order. There will be no offerings to save all the shorts outstanding.
  • C
    Cured
    Same with the Director of Baylor Medical’s Hematological Research.
    Bullish
  • S
    Stan
    Imagine you sold pre market when they just released that positive news :D
  • C
    Cured
    Any Ideas What the Share Price will be as we get closer to this binary Readout? > When will the market begin to Appreciate this massive value?
  • d
    dave
    The paid pumper w 12 aliases has never seen shorts more worried...
  • m
    mike
    Like I said if MNKD can have a billion dollar market cap then SLS can have a 1.5 billion dollar market cap. The multiple cancers SLS is showing unheard of results will make this a buyout by January 2024 in the 50-75 range plus!
  • C
    Cured
    The Chair of MD Andersons Leukemia dept running the GPS Phase 3, sees the trial Data, and requested Expanded Access beyond the Cr2 treated patients, to include Cr 1 and ASCT patients.
    Essentially, Confirms Gps is doing what it should and the ultimate overall AML market is 5x CR 2 appx $800M.
    Bullish
  • M
    MauiRunner
    A Glimpse of SLS's Future - this is a direct AML Market comp WSJ Jazz Nears Deal to Buy Celator for About $1.5 Billion / Celator’s share price rose more than 400% in a single day. Jazz would pay roughly double Celator’s market value of about $740 million, a lofty premium for a company with a promising leukemia drug but no revenue
    Bullish
  • C
    Cured
    Anyone with a 90 Day Investing Horizon - Pile In. We are now in the doldrums at the bottom and will be greatly rewarded when the Market, soon begins to appreciate SLS‘s multibillion catalysts - esp as we get closer to enrollment completion.
    The Chairman of MD Andersons Leukemia department requesting Expanded access Confirms Gps will be a multibillion Immunotherapy for AML patients.

    3D licensing deal is for $193 M in Milestones - the big money starts with the P3. A positive result triggers
    $25M
    + 25M in short order.

    Bottom line - Zero Dilution, plenty of cash to get well past the Gps P3 in a couple few qtrs, and a positive result will trigger a $25M milestone payment from 3D Med and another shortly thereafter.
    No offerings for shorts to cover with, just a massive squeeze.
    Bullish
  • j
    james
    "The final analysis now shows that GPS extends patients' overall survival to 21 months vs 5.4 with BAT
    These follow-up data build upon the initially published clinical results from the Phase 1/2 study of GPS in AML patients in CR2 and provide further evidence that this novel immunotherapeutic vaccine approach may improve outcomes for patients in this setting, who often harbor measurable residual disease and have a poor prognosis if they are unable to undergo allotransplant," said Javier Pinilla-Ibarz, MD, PhD, principal investigator of the trial. Pinilla-lbarz also is the director of Immunotherapy for Malignant Hematology at the Moffitt Cancer Center in. Tampa, Florida.

    SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The Company’s lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications.

    In January 2020, SELLAS commenced a pivotal Phase 3 study of GPS in acute myeloid leukemia (AML). SELLAS is also currently conducting a Phase 1/2 open label basket study of GPS in combination with the anti-PD-1 therapy pembrolizumab in collaboration with Merck (known as MSD outside of the United States and Canada). The primary indication currently being studied is ovarian cancer (second or third line). SELLAS has received Orphan Drug designations for GPS from the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for AML, malignant pleural mesothelioma (MPM), and multiple myeloma (MM). GPS has also received Fast Track designation for AML, MPM and MM from the FDA.
Advertisement
Advertisement